All In Biotech

Drug Trial Radar · NCT05704036

Estrogen Supplementation and Bone Health in Women With CF

Estrogen Supplementation and Bone Health in Women With CF (STURDY)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

May 2, 2023

Primary completion

Jan 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cystic Fibrosis Foundation
First posted
Jan 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 0 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: * How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health? * Is a study of transdermal estradiol (estrogen skin patches) feasible in this group? * How does transdermal estradiol impact bone health and quality of life? Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception. Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.

Conditions

  • Cystic Fibrosis
  • Hypoestrogenism

Interventions

  • Transdermal estrogenDrug

    Transdermal estradiol 0.1 mg/day, applied once weekly

  • ProgesteroneDrug

    Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)Time frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.